<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H3FBF35511DDC44FF877E3AFC8F58EA29" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1840 IH: Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-03-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1840</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170330">March 30, 2017</action-date><action-desc><sponsor name-id="P000594">Mr. Paulsen</sponsor> (for himself, <cosponsor name-id="T000460">Mr. Thompson of California</cosponsor>, <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>, <cosponsor name-id="W000799">Mr. Walz</cosponsor>, <cosponsor name-id="R000515">Mr. Rush</cosponsor>, and <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Internal Revenue Code of 1986 to allow a credit against tax for clinical testing
			 expenses for qualified infectious disease drugs and rapid diagnostic
			 tests.</official-title></form>
	<legis-body id="HED931F2C2745448D854DF4F8A8ABDA00" style="OLC">
 <section id="H1DCC010DBD3543E5BE9F87A462F043CC" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017</short-title></quote>.</text> </section><section id="H9B1C20D573884E2CB0D94EDC8F18C460" section-type="subsequent-section"><enum>2.</enum><header>Clinical testing expenses for qualified infectious disease products</header> <subsection commented="no" id="H4AF5989272DA43B8B7B4B7ECED5D7E8B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text>
				<quoted-block display-inline="no-display-inline" id="H841059E6BD5A4762B906BE3559F915F9" style="OLC">
					<section commented="no" id="HD692D96488DF4FFDA1F39BF5E12BBE65"><enum>45S.</enum><header>Clinical testing expenses for qualified infectious disease products</header>
 <subsection commented="no" id="H37C87AE50B7748D6ACF607E0765353EA"><enum>(a)</enum><header>General rule</header><text>For purposes of section 38, the qualified infectious disease product credit determined under this section for the taxable year is an amount equal to 50 percent of the qualified clinical testing expenses for the taxable year.</text>
 </subsection><subsection commented="no" id="HBDA0FBD34DA34F85A3217F8810F1AD9C"><enum>(b)</enum><header>Qualified clinical testing expenses</header><text>For purposes of this section—</text> <paragraph commented="no" id="HB9CB986B207A47AE93FE0BFB7571AB07"><enum>(1)</enum><header>Qualified clinical testing expenses</header> <subparagraph commented="no" id="HAB351EC303AE469DBF5AFA47B4EC4FF0"><enum>(A)</enum><header>In general</header><text>Except as otherwise provided in this paragraph, the term <term>qualified clinical testing expenses</term> means the amounts which are paid or incurred by the taxpayer during the taxable year which would be described in subsection (b) of section 41 if such subsection were applied with the modifications set forth in subparagraph (B).</text>
 </subparagraph><subparagraph commented="no" id="H8C63D1FE8A3B4F5386E7FF32AE1C013F"><enum>(B)</enum><header>Modifications</header><text>For purposes of subparagraph (A), subsection (b) of section 41 shall be applied—</text> <clause commented="no" id="HF8D80D6B05404507B5C957B295F2E66F"><enum>(i)</enum><text>by substituting <quote>clinical testing</quote> for <quote>qualified research</quote> each place it appears in paragraphs (2) and (3) of such subsection, and</text>
 </clause><clause commented="no" id="HDCA7269ED03A4B4495A725B8A6134F53"><enum>(ii)</enum><text>by substituting <quote>100 percent</quote> for <quote>65 percent</quote> in paragraph (3)(A) of such subsection.</text> </clause></subparagraph><subparagraph commented="no" id="H85794FCDD5394C7B9CFB016423AAC2CE"><enum>(C)</enum><header>Exclusion for amounts funded by grants, etc</header><text>The term <term>qualified clinical testing expenses</term> shall not include any amount to the extent such amount is funded by any grant, contract, or otherwise by another person (or any governmental entity).</text>
 </subparagraph><subparagraph commented="no" id="H18CFECC03DA441588F4A1BCB51BB237B"><enum>(D)</enum><header>Special rule</header><text>For purposes of this paragraph, section 41 shall be deemed to remain in effect for periods after enactment of this section.</text>
								</subparagraph></paragraph><paragraph commented="no" id="HD0707B76201A4422B1079B41E01E4CF5"><enum>(2)</enum><header>Clinical testing</header>
 <subparagraph commented="no" id="H8B3EB4B1BCC64727BC047B023DB5DD42"><enum>(A)</enum><header>In general</header><text>The term <term>clinical testing</term> means any human clinical testing—</text> <clause commented="no" id="H19B28EA3E8464B879F01B11902A859F1"><enum>(i)</enum><text>which is carried out under an exemption for a drug being tested as an antibiotic or antifungal drug under section 505(i) of the Federal Food, Drug, and Cosmetic Act (or regulations issued under such section),</text>
 </clause><clause commented="no" id="HE2CE16AE2EED4C6AB9FA3B5D39C76D5C"><enum>(ii)</enum><text>which occurs before the date on which an application with respect to such drug is approved under section 505(b) of such Act or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Service Act, and</text>
 </clause><clause commented="no" id="H0E8444CC68184C1898AFF01073D0544F"><enum>(iii)</enum><text display-inline="yes-display-inline">which is conducted by or on behalf of the taxpayer to whom exemption under section 505(i) of such Act is granted.</text>
 </clause></subparagraph><subparagraph commented="no" id="H6F7024949BDC4A4BADB0628FD384FF19"><enum>(B)</enum><header>Testing must be related to use as qualified infectious disease product</header><text>Human clinical testing shall be taken into account under subparagraph (A) only to the extent such testing is related to the use of the drug as a qualified infectious disease product.</text>
								</subparagraph></paragraph></subsection><subsection commented="no" id="H480BAD1AAF374C4D9CC363AEFF3C8EE0"><enum>(c)</enum><header>Coordination with credit for increasing research expenditures</header>
 <paragraph commented="no" id="H1364F2E578A64267A803936ABBE7D0FC"><enum>(1)</enum><header>In general</header><text>Except as provided in paragraph (2), any qualified clinical testing expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section 41 for such taxable year.</text>
 </paragraph><paragraph commented="no" id="H55BA4A257C6E4FF2BC3337CC24527144"><enum>(2)</enum><header>Expenses included in determining base period research expenses</header><text>Any qualified clinical testing expenses for any taxable year which are qualified research expenses (within the meaning of section 41(b)) shall be taken into account in determining base period research expenses for purposes of applying section 41 to subsequent taxable years.</text>
							</paragraph></subsection><subsection commented="no" id="HD48862DDB9EA48DAA945886ED9DFCF19"><enum>(d)</enum><header>Definitions and special rules</header>
 <paragraph commented="no" id="HC6B6D5D1F1B940BCA4FC09745B89F507"><enum>(1)</enum><header>Qualified infectious disease product</header><text>For purposes of this section, the term <term>qualified infectious disease product</term> means any drug or biological product for human use that—</text> <subparagraph id="H15C5508C66084FF68FAC18A267C191C0"><enum>(A)</enum><text display-inline="yes-display-inline">is intended to treat a serious or life-threatening infection, including those caused by—</text>
 <clause id="H56BD5315F7E1481CA3B751DF24F6D6D8"><enum>(i)</enum><text>an antibacterial or antifungal resistant pathogen (including novel or emerging infectious pathogens), or</text>
 </clause><clause id="HC292B3BAFE7645FCBB415BCE57680DB4"><enum>(ii)</enum><text>qualifying pathogens listed by the Secretary of Health and Human Services under section 505E(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref> et seq.), and</text>
 </clause></subparagraph><subparagraph id="HD69A97F1E13E425A89158AF4481686F7"><enum>(B)</enum><text>is intended to treat an infection for which there is an unmet medical need as defined by the Secretary of Health and Human Services.</text>
								</subparagraph></paragraph><paragraph commented="no" id="H4DF77D35F5A144A89E5BF71243EC843F"><enum>(2)</enum><header>Special limitation on foreign testing</header>
 <subparagraph id="HDC2672CD910F4CDF87180D9D55B92808"><enum>(A)</enum><header>In general</header><text>No credit shall be allowed under this section with respect to any clinical testing conducted outside the United States unless—</text>
 <clause commented="no" id="H7E9791E44EBF415F87D1259547B49CC4"><enum>(i)</enum><text>such testing is conducted outside the United States because there is an insufficient testing population in the United States, and</text>
 </clause><clause commented="no" id="HA13E723ECAAF420F885523E49C772254"><enum>(ii)</enum><text display-inline="yes-display-inline">such testing is conducted by a United States person or by any other person who is not related to the taxpayer to whom exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act is granted.</text>
 </clause></subparagraph><subparagraph display-inline="no-display-inline" id="H37F304E357294B39A20FCBF8E028FB03"><enum>(B)</enum><header>Insufficient testing population</header><text>For purposes of this section, the testing population in the United States is insufficient if there are not within the United States the number of available and appropriate human subjects needed to produce reliable and timely data from the clinical investigation.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HDDD51D2CE1E44068BFAF502F848FFE58"><enum>(3)</enum><header>Certain rules made applicable</header><text>Rules similar to the rules of paragraphs (1) and (2) of section 41(f) shall apply for purposes of this section.</text>
 </paragraph><paragraph commented="no" id="HBBAE1C584C0E4F44BF94387EBB8B1BBE"><enum>(4)</enum><header>Election</header><text>This section shall apply to any taxpayer for any taxable year only if such taxpayer elects (at such time and in such manner as the Secretary may by regulations prescribe) to have this section apply for such taxable year.</text>
							</paragraph></subsection><subsection commented="no" id="H015CDCE72149460D8D9D4D7D406AD362"><enum>(e)</enum><header>Transferability</header>
 <paragraph commented="no" id="H6665CE39D1984913B0120DF3AFAB041E"><enum>(1)</enum><header>In general</header><text>Any taxpayer holding a credit under this section may transfer for valuable consideration unused but otherwise allowable credit for use by a qualified pharmaceutical research taxpayer. A taxpayer that transfers any amount of credit under this section shall file a notification of such transfer to the Secretary in accordance with procedures and forms prescribed by the Secretary.</text>
 </paragraph><paragraph commented="no" id="H25A1944941594C4DA48A4C213970AC5D"><enum>(2)</enum><header>Use of transferred credit</header><text>Any qualified pharmaceutical research taxpayer that receives credit that has been transferred shall use such credit for the taxable year in which the transfer occurred. Any unused amounts of such credit may be carried back or forward to other taxable years in accordance with section 39.</text>
 </paragraph><paragraph commented="no" id="HAB4B166112934A4FB8FE2E29F317FBE6"><enum>(3)</enum><header>Definition of qualified pharmaceutical research taxpayer</header><text>For purposes of this section, the term <term>qualified pharmaceutical research taxpayer</term> means any domestic corporation the primary mission of which is pharmaceutical research or development.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HA44DCB3A6CF64FBBA5AF14A2B2FDEE8E"><enum>(b)</enum><header>Made part of business credit</header><text display-inline="yes-display-inline">Section 38(b) of such Code is amended by striking <quote>plus</quote> at the end of paragraph (35), by striking the period at the end of paragraph (36) and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="HEBDB7F17C17749A886A71EB01D61F231" style="OLC"> <paragraph id="H70F10D46DE6F4E56B90FFA3D711B4EC0"><enum>(37)</enum><text display-inline="yes-display-inline">the qualified infectious disease product credit determined under section 45S(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H61D6A6C15CF044799876B59B69D129DD"><enum>(c)</enum><header>Clerical amendments</header><text>The table of sections for subpart D of part IV of subchapter A of chapter 1 of such Code is amended by adding at the end the following new item:</text>
				<quoted-block display-inline="no-display-inline" id="H30C6231A84B9474291A05EDA6F55EF71" style="OLC">
					<toc regeneration="no-regeneration">
						<toc-entry level="section">Sec. 45S. Clinical testing expenses for qualified infectious disease products.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H6CEA0255EA9845FA875EF2A2308EFCAC"><enum>(d)</enum><header>Effective date</header><text>The amendment made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act.</text>
			</subsection></section><section display-inline="no-display-inline" id="H500734453F5E40FE824FBF36EEB874FB"><enum>3.</enum><header>Clinical testing expenses for rapid infectious diseases diagnostic tests</header>
 <subsection id="HC8641F38EAF848FFB7060E225510A650"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986, as amended by section 2, is amended by adding at the end the following new section:</text>
				<quoted-block display-inline="no-display-inline" id="H9E3E359EAAFD4224BFF38E8F477E2793" style="OLC">
					<section id="H29887AD86B0D4AC3A7AD70BFBD780DA0"><enum>45T.</enum><header>Clinical testing expenses for rapid infectious diseases diagnostic tests</header>
 <subsection id="H516613EEDC6F47D8B9CF813CE5253D96"><enum>(a)</enum><header>General rule</header><text>For purposes of section 38, the credit determined under this section for the taxable year is an amount equal to 50 percent of the qualified clinical testing expenses for the taxable year.</text>
 </subsection><subsection id="H21C5A14EF8BB42B2A4EE3C7289C9BBA9"><enum>(b)</enum><header>Qualified clinical testing expenses</header><text>For purposes of this section—</text> <paragraph id="H2C85B3E9949946F6939BB5B5581F368D"><enum>(1)</enum><header>Qualified clinical testing expenses</header> <subparagraph id="H1890B544A8534325973C87BD3EC06CC7"><enum>(A)</enum><header>In general</header><text>Except as otherwise provided in this paragraph, the term <term>qualified clinical testing expenses</term> means the amounts which are paid or incurred by the taxpayer during the taxable year which would be described in subsection (b) of section 41 if such subsection were applied with the modifications set forth in subparagraph (B).</text>
 </subparagraph><subparagraph id="HB1AB348BDD5045DDA06DD69221968A7C"><enum>(B)</enum><header>Modifications</header><text>For purposes of subparagraph (A), subsection (b) of section 41 shall be applied—</text> <clause id="HAF0B6A7CA31243B2BAD17071965515FF"><enum>(i)</enum><text>by substituting <quote>clinical testing</quote> for <quote>qualified research</quote> each place it appears in paragraphs (2) and (3) of such subsection, and</text>
 </clause><clause id="HD96D68EB170A4E18A0E7491E3FC05E7E"><enum>(ii)</enum><text>by substituting <quote>100 percent</quote> for <quote>65 percent</quote> in paragraph (3)(A) of such subsection.</text> </clause></subparagraph><subparagraph id="H97B676FF7DDC4C7EBD9EDA663BD97056"><enum>(C)</enum><header>Exclusion for amounts funded by grants, etc</header><text>The term <term>qualified clinical testing expenses</term> shall not include any amount to the extent such amount is funded by any grant, contract, or otherwise by another person (or any governmental entity).</text>
 </subparagraph><subparagraph id="H887CAB2BA18F462B8285122210298257"><enum>(D)</enum><header>Special rule</header><text>For purposes of this paragraph, section 41 shall be deemed to remain in effect for periods after enactment of this section.</text>
								</subparagraph></paragraph><paragraph id="HAD71ED7DE81B43D3BAD11E4608508F22"><enum>(2)</enum><header>Clinical testing</header>
 <subparagraph id="H3D26E0F90B5245F0B63DBB89AB50C3C2"><enum>(A)</enum><header>In general</header><text>The term <term>clinical testing</term> means any human clinical testing—</text> <clause id="H78760BBEDF0A463B9F86DD13DE897BEC"><enum>(i)</enum><text>which is carried out under an exemption for a device being tested under section 520(g) of the Federal Food, Drug, and Cosmetic Act (or regulations issued under such section),</text>
 </clause><clause id="H1020A07BCEC94ED38C37EF0CF772F073"><enum>(ii)</enum><text>which is related only to such use as a qualified rapid infectious diseases diagnostic test,</text> </clause><clause id="HB830043905064DC3957D0D3C23F8796A"><enum>(iii)</enum><text>which occurs before the date on which an application with respect to such device receives premarket approval, if required, under section 515 of such Act, or receives clearance, if required, under section 510(k) of such Act, and</text>
 </clause><clause id="H4D212D6B4FDD4D68BDD8924FF67A3DC4"><enum>(iv)</enum><text>which is conducted by or on behalf of the taxpayer to whom the exemption under section 520(g) of such Act was granted.</text>
									</clause></subparagraph></paragraph></subsection><subsection id="H72A80993222F401687BD5FD9E7236DAC"><enum>(c)</enum><header>Coordination with credit for increasing research expenditures</header>
 <paragraph id="H3E092E05C11741959EA7B9BF9CA92287"><enum>(1)</enum><header>In general</header><text>Except as provided in paragraph (2), any qualified clinical testing expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section 41 for such taxable year.</text>
 </paragraph><paragraph id="HE11089E586FC4C738A6475483A95E635"><enum>(2)</enum><header>Expenses included in determining base period research expenses</header><text>Any qualified clinical testing expenses for any taxable year which are qualified research expenses (within the meaning of section 41(b)) shall be taken into account in determining base period research expenses for purposes of applying section 41 to subsequent taxable years.</text>
							</paragraph></subsection><subsection id="HEC5952240D8F4BD7BCCA81F117A595DF"><enum>(d)</enum><header>Definitions and special rules</header>
 <paragraph id="HDC76774D136D425C8E8ACD5798B797BD"><enum>(1)</enum><header>Qualified rapid infectious diseases diagnostic test</header><text>For purposes of this section, the term <term>qualified rapid infectious diseases diagnostic test</term> means an in-vitro diagnostic (IVD) device that provides results in less than four hours and that is used to identify or detect the presence, concentration, or characteristics of a serious or life-threatening infection, including those caused by (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens or (2) qualifying pathogens listed by the Secretary of Health and Human Services under Chapter V (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref> et seq.) section 505E(f).</text>
							</paragraph><paragraph id="H57EC6A75458446BF93BF76C1C8CC1B80"><enum>(2)</enum><header>Special limitation on foreign testing</header>
 <subparagraph id="H0D13D6786A844AFB88A46C9E89D9E8B4"><enum>(A)</enum><header>In general</header><text>No credit shall be allowed under this section with respect to any clinical testing conducted outside the United States unless—</text>
 <clause id="H768C4DE3E2BA44B9A03E66DFE31E0B2A"><enum>(i)</enum><text>such testing is conducted outside the United States because there is an insufficient testing population in the United States, and</text>
 </clause><clause id="H37922EE403E7495F89FB0547F5B1EF76"><enum>(ii)</enum><text display-inline="yes-display-inline">such testing is conducted by a United States person or by any other person who is not related to the taxpayer to whom the exemption under section 520(g) of Federal Food, Drug, and Cosmetic Act was granted.</text>
 </clause></subparagraph><subparagraph id="H6648CD6E929D4F009A2563AAE31C2F14"><enum>(B)</enum><header>Insufficient testing population</header><text>For purposes of this section, the testing population in the United States is insufficient if there are not within the United States the number of available and appropriate human subjects needed to produce reliable and timely data from the clinical investigation.</text>
 </subparagraph></paragraph><paragraph id="H97402AF39E7C493C998071FEAAC1F0C8"><enum>(3)</enum><header>Certain rules made applicable</header><text>Rules similar to the rules of paragraphs (1) and (2) of section 41(f) shall apply for purposes of this section.</text>
 </paragraph><paragraph id="H8F8E9994FF1F46768D6A2CCDDF442BAC"><enum>(4)</enum><header>Election</header><text>This section shall apply to any taxpayer for any taxable year only if such taxpayer elects (at such time and in such manner as the Secretary may by regulations prescribe) to have this section apply for such taxable year.</text>
							</paragraph></subsection><subsection id="H66C2F6FB91A94E4EB652EBCC0A8EB15D"><enum>(e)</enum><header>Transferability</header>
 <paragraph id="H7C4F8C3BC3A347BCBCF85BEEAB0037DB"><enum>(1)</enum><header>In general</header><text>Any taxpayer holding a credit under this section may transfer for valuable consideration unused but otherwise allowable credit for use by a qualified diagnostics research taxpayer. A taxpayer that transfers any amount of credit under this section shall file a notification of such transfer to the Secretary in accordance with procedures and forms prescribed by the Secretary.</text>
 </paragraph><paragraph id="H17317182D6194E53AC8E0951B0E025EE"><enum>(2)</enum><header>Use of transferred credit</header><text>Any qualified diagnostics research taxpayer that receives credit that has been transferred shall use such credit for the taxable year in which the transfer occurred. Any unused amounts of such credit may be carried back or forward to other taxable years in accordance with section 39.</text>
 </paragraph><paragraph id="H7638BA114F104B7D821C833CCC94E3A4"><enum>(3)</enum><header>Definition of qualified diagnostics research taxpayer</header><text>For purposes of this section, the term <term>qualified diagnostics research taxpayer</term> means any domestic corporation that derives—</text> <subparagraph id="HC7C0F87CC14042268AF9DF2707B98F32"><enum>(A)</enum><text>any gross income from research or development on diagnostic tests used to identify or detect the presence, concentration or characteristics of a serious or life-threatening infectious disease or pathogen; or</text>
 </subparagraph><subparagraph id="H4F76D36F52CF4B169E4CF24020D3C5C7"><enum>(B)</enum><text>any gross income from research or development on qualified infectious disease products within the meaning given to such term in section 505E(g) of the Federal, Food, Drug, and Cosmetic Act; or</text>
 </subparagraph><subparagraph id="HE13EBE4686DB438DBE573F3698240149"><enum>(C)</enum><text>more than 50 percent of its gross income from activities related to health care.</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HB24D5B1851EF4F8086DE0FDAA4B3403F"><enum>(b)</enum><header>Made part of business credit</header><text>Section 38(b) of such Code, as amended by section 2, is amended by striking <quote>plus</quote> at the end of paragraph (36), by striking the period at the end of paragraph (37) and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text>
				<quoted-block display-inline="no-display-inline" id="HDCCD191645034E07B8E0CC657CFA8EF9" style="OLC">
 <paragraph id="H6F6D0CD3E28148BA9A5F3F36D729EE0D"><enum>(38)</enum><text display-inline="yes-display-inline">the credit determined under section 45T(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="H6444090B6E5A49759694BDB2DE8AB9EA"><enum>(c)</enum><header>Clerical amendment</header><text display-inline="yes-display-inline">The table of sections for subpart D of part IV of subchapter A of chapter 1 of such Code, as amended by section 2, is amended by adding at the end the following new item:</text>
				<quoted-block display-inline="no-display-inline" id="HCEE643928A5743E380FEE8645D70AA1D" style="OLC">
					<toc regeneration="no-regeneration">
						<toc-entry level="section">Sec. 45T. Clinical testing expenses for rapid infectious diseases diagnostic tests.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H5C5850C298E84752B30C786F7F258501"><enum>(d)</enum><header>Effective date</header><text>The amendment made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act.</text>
			</subsection></section></legis-body></bill>


